Trial Profile
Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 May 2017
Price :
$35
*
At a glance
- Drugs Rabeprazole (Primary) ; Famotidine
- Indications Peptic ulcer
- Focus Therapeutic Use
- Acronyms ASP(PPI-H2RA)
- 20 Apr 2017 Status changed from active, no longer recruiting to completed.
- 15 Sep 2016 Results published in the Gastroenterology.
- 11 Sep 2016 Primary endpoint (Recurrent non-variceal upper GI bleeding) has not been met, according to results published in the Gastroenterology.